The Centers for Disease Control and Prevention states that there are an estimated 11 to 21 million cases of typhoid fever annually. It is also reported that typhoid and paratyphoid fever are responsible for 135,000 to 230,000 deaths worldwide each year. This data highlights the need for pipeline expansion to eliminate typhoid as a public health threat. Further, the rise of multidrug-resistant Salmonella Typhi is stimulating the development of novel antibiotics and other alternative treatments.
The Typhoid Fever Drug Pipeline Report by Expert Market Research gives comprehensive insights into typhoid fever drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for typhoid fever. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from typhoid fever.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to typhoid fever are covered.
Typhoid fever is caused by the bacterium Salmonella typhi and is spread through contaminated food or water. The bacterial infection can be life-threatening if left untreated. Symptoms include high fever, headache, fatigue, and abdominal pain, among others. Typhoid fever is typically treated with antibiotics. However, antimicrobial resistance is common and severe cases may require hospitalization. Typhoid fever is common in regions such as Africa, South-East Asia, Eastern Mediterranean, and Western Pacific regions.
There is an increased interest towards the development of vaccines that provide longer-lasting immunity and are suitable for all age groups. Further, growing research into combination vaccines and the rise in mass vaccination campaigns are expected to positively impact the pipeline landscape for typhoid fever.
This section of the report covers the analysis of typhoid fever drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for typhoid fever.
The drug molecules categories covered under typhoid fever pipeline analysis include vaccines, small molecule antibiotics, monoclonal antibodies, and peptide-based therapeutics. The treatment for typhoid fever depends on the patient’s overall health and antibiotic resistance in the region. Antibiotics are commonly prescribed to the patient to kill the Salmonella Typhi bacteria. Common antibiotics include ciprofloxacin, azithromycin, and ceftriaxone.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for typhoid fever.
The EMR report for the typhoid fever drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in typhoid fever clinical trials:
Leading drugs currently in pipeline are as follows:
The randomized controlled clinical study was designed to compare and evaluate the efficacy of a combination of azithromycin and cefixime against azithromycin alone in outpatients with suspected or confirmed uncomplicated typhoid fever in South Asia. This Phase IV interventional trial has enrolled around 1500 participants.
Sponsored by PT Bio Farma, this Phase II/III trial aims to assess how long the Vi-DT typhoid vaccine remains effective by measuring antibody titer in individuals 2, 3, 4, and 5 years after vaccination. The study has enrolled around 188 Indonesian adults, adolescents, children, and infants.
The objective of this clinical trial is to investigate the efficacy of a single dose of the Typbar-TCV® vaccine against blood culture-confirmed typhoid fever. The vaccine was administered to children aged 9 months to under 16 years during a mass vaccination campaign in Kisantu, Democratic Republic of Congo (DRC). Sponsored by the International Vaccine Institute, the study is in Phase IV clinical development and has an estimated 48,000 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Typhoid Fever Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for typhoid fever. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the typhoid fever pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share